
DBD Stock Forecast & Price Target
DBD Analyst Ratings
Bulls say
Diebold Nixdorf is supported by improving execution, tighter cost controls, and expanding margin visibility across both Banking and Retail, with management maintaining 2026/2027 adj. EBITDA forecasts and reiterating a $510M-$535M 2026 EBITDA range. The company’s fundamentals are strengthened by healthy order entry and a sequentially higher $790M backlog, plus robust demand in ATMs, POS, SCO, and Smart Vision AI, including 26% Y/Y Retail sales growth in 1Q26 and notable Banking wins in North America, Europe, and India. Its low 1.2x net leverage, ~$680M liquidity, $21M of 1Q26 FCF, and expected 2026 FCF of $255M-$270M support buybacks and provide financial flexibility as Services margins improve and FCF remains well above adj. net income.
Bears say
Diebold Nixdorf is facing a cautious near-term setup because its 1Q26 adjusted EBITDA estimate was cut by $5M to $90M, reflecting weaker Services gross margin from remaining Oracle Field Services deployment and training costs in North America. While full-year 2026 and 2027 estimates were unchanged, the need to trim quarterly profitability highlights ongoing execution pressure, especially as Banking upgrade and replacement activity can be lumpy and unpredictable. The bearish view is reinforced by external risks from tariffs, supply-chain disruptions, FX volatility, and concentrated ownership, with only about 150K shares traded daily and roughly 60% of common shares held by debtholders.
This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.
DBD Analyst Forecast & Price Prediction
Start investing in DBD
Order type
Buy in
Order amount
Est. shares
0 shares